Isoflavones are safe compounds for therapeutical applications - Evaluation of in vitro data

Gynecological Endocrinology

Volumn 25, Issue 9, 2009, Pages 554-580

  Reiter, Evelyne ^a,b   Beck, Verena ^a   Medjakovic, Svjetlana ^a,b   Jungbauer, Alois ^a,b  

^a UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^b INSTITUTE FOR MICROELECTRONICS   (Austria)

Author keywords

AhR; Cancer; ER; In vitro; Isoflavones; Metabolism; PPAR

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 HYDROXY O DESMETHYLANGOLENSIN; BIOCHANIN A; DAIDZEIN; DAIDZEIN GLUCURONIDE; DAIDZIN; DIHYDRODAIDZEIN; DIHYDROGENISTEIN; DRUG METABOLITE; EQUOL; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FORMONONETIN; GENISTEIN; GENISTEIN GLUCURONIDE; GENISTIN; GLYCITEIN; ISOFLAVONE; O DESMETHYLANGOLENSIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHYTOESTROGEN; SOYBEAN PROTEIN; STEROID RECEPTOR; SULFATASE; SULFOTRANSFERASE; TETRAHYDRODAIDZEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; BONE STRUCTURE; CANCER INHIBITION; CLINICAL EVALUATION; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG USE; ENZYME ACTIVITY; ENZYME METABOLISM; ESTROGEN ACTIVITY; ESTROGEN METABOLISM; GROWTH RETARDATION; GROWTH STIMULATION; HUMAN; IN VITRO STUDY; INFLAMMATION; METABOLIC DISORDER; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; REVIEW; SOYBEAN; STEROID METABOLISM; TISSUE SPECIFICITY; TRANSACTIVATION; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION; XENOGRAFT;

AROMATASE; HUMANS; ISOFLAVONES; RECEPTORS, ESTROGEN;

EID: 70350639632     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590802596461     Document Type: Review

References (171)

1. Iwasaki M, Inoue M, Otani T, Sasazuki S, Kurahashi N, Miura T, Yamamoto S, Tsugane S. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J Clin Oncol 2008;26:1677-1683.
2. Segars JH, Driggers PH. Estrogen action and cytoplasmic signaling cascades. I. Membrane-associated signaling complexes. Trends Endocrinol Metab 2002;13:349-354.
3. Soto AM, Sonnenschein C, Chung KL, Fernandez MF, Olea N, Serrano FO. The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. Environ Health Perspect 1995;103:113-122.
4. Metzger D, White JH, Chambon P. The human oestrogen receptor functions in yeast. Nature 1988;334:31-36.
5. Fang H, Tong W, Shi LM, Blair R, Perkins R, Branham W, Hass BS, Xie Q, Dial SL, Moland CL, et al. Structure- activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. Chem Res Toxicol 2001;14:280-294.
6. Choi SY, Ha TY, Ahn JY, KimSR, Kang KS, Hwang IK, Kim S. Estrogenic activities of isoflavones and flavones and their structure-activity relationships. Planta Med 2008;74:25-32.
7. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson J-A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors {alpha} and {beta}. Endocrinology 1997;138:863-870. (Pubitemid 27089735)
8. Collins BM, McLachlan JA, Arnold SF. The estrogenic and antiestrogenic activities of phytochemicals with the human estrogen receptor expressed in yeast. Steroids 1997;62:365-372.
9. Liu J, Burdette JE, Xu H, Gu C, van Breemen RB, Bhat KP, Booth N, Constantinou AI, Pezzuto JM, Fong HH, et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem 2001;49:2472-2479.
10. Breithofer A, Graumann K, Scicchitano MS, Karathanasis SK, Butt TR, Jungbauer A. Regulation of human estrogen receptor by phytoestrogens in yeast and human cells. J Steroid Biochem Mol Biol 1998;67:421-429.
11. Beck V, Unterrieder E, Krenn L, Kubelka W, Jungbauer A. Comparison of hormonal activity (estrogen, androgen and progestin) of standardized plant extracts for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 2003;84:259-268.
12. Jungbauer A, Beck V. Yeast reporter system for rapid determination of estrogenic activity. J Chromatogr B Anal Technol Biomed Life Sci 2002;777:167-178.
13. Breinholt V, Larsen JC. Detection of weak estrogenic flavonoids using a recombinant yeast strain and a modified MCF7 cell proliferation assay. Chem Res Toxicol 1998;11:622-629.
14. Promberger A, Dornstauder E, Fruhwirth C, Schmid ER, Jungbauer A. Determination of estrogenic activity in beer by biological and chemical means. J Agric Food Chem 2001;49:633-640.
15. Dornstauder E, Jisa E, Unterrieder I, Krenn L, Kubelka W, Jungbauer A. Estrogenic activity of two standardized red clover extracts (Menoflavon) intended for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 2001;78:67-75.
16. Miksicek RJ. Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human estrogen receptor. J Steroid Biochem Mol Biol 1994;49:153-160.
17. Hwang CS, Kwak HS, Lim HJ, Lee SH, Kang YS, Choe TB, Hur HG, Han KO. Isoflavone metabolites and their in vitro dual functions: they can act as an estrogenic agonist or antagonist depending on the estrogen concentration. J Steroid Biochem Mol Biol 2006;101:246-253.
18. Kostelac D, Rechkemmer G, Briviba K. Phytoestrogens modulate binding response of estrogen receptors alpha and beta to the estrogen response element. J Agric Food Chem 2003;51:7632-7635.
19. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998;139:4252-4263.
20. Song TT, Hendrich S, Murphy PA. Estrogenic activity of glycitein, a soy isoflavone. J Agric Food Chem 1999;47: 1607-1610.
21. Zhang Y, Song TT, Cunnick JE, Murphy PA, Hendrich S. Daidzein and genistein glucuronides in vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations. J Nutr 1999;129:399-405.
22. Muthyala RS, Ju YH, Sheng S, Williams LD, Doerge DR, Katzenellenbogen BS, Helferich WG, Katzenellenbogen JA. Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg Med Chem 2004;12:1559-1567.
23. Milligan SR, Kalita JC, Heyerick A, Rong H, De Cooman L, De Keukeleire D. Identification of a potent phytoestrogen in hops (Humulus lupulus L.) and beer. J Clin Endocrinol Metab 1999;84:2249-2252.
24. Bovee TFH, Helsdingen RJR, Rietjens IMCM, Keijer J, Hoogenboom RLAP. Rapid yeast estrogen bioassays stably expressing human estrogen receptors [alpha] and [beta], and green fluorescent protein: a comparison of different compounds with both receptor types. J Steroid Biochem Mol Biol 2004;91:99-109.
25. Federici E, Touche A, Choquart S, Avanti O, Fay L, Offord E, Courtois D. High isoflavone content and estrogenic activity of 25 year-old Glycine max tissue cultures. Phytochemistry 2003;64:717-724.
26. Chrzan BG, Bradford PG. Phytoestrogens activate estrogen receptor b1 and estrogenic responses in human breast and bone cancer cell lines. Mol Nutr Food Res 2007;51:171-177.
27. Harris DM, Besselink E, Henning SM, Go VLW, Heber D. Phytoestrogens induce differential estrogen receptor alphaor beta-mediated responses in transfected breast cancer cells. Exp Biol Med 2005;230:558-568.
28. Mueller SO, Simon S, Chae K, Metzler M, Korach KS. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor a (ERa) and estrogenic responses in human cells. Toxicol Sci 2004;80:14-25.
29. Gutendorf B, Westendorf J. Comparison of an array of in vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens. Toxicology 2001;166:79-89.
30. Hunter DS, Hodges LC, Vonier PM, Fuchs-Young R, Gottardis MM, Walker CL. Estrogen receptor activation via activation function 2 predicts agonism of xenoestrogens in normal and neoplastic cells of the uterine myometrium. Cancer Res 1999;59:3090-3099.
31. Arnold SF, Collins BM, Robinson MK, Guillette Jr LJ, McLachlan JA. Differential interaction of natural and synthetic estrogens with extracellular binding proteins in a yeast estrogen screen. Steroids 1996;61:642-646.
32. Hasenbrink G, Sievernich A, Wildt L, Ludwig J, Lichtenberg- Frate H. Estrogenic effects of natural and synthetic compounds including tibolone assessed in Saccharomyces cerevisiae expressing the human estrogen {alpha} and {beta} receptors. FASEB J 2006;20:1552-1554.
33. Sonneveld E, Jansen HJ, Riteco JAC, Brouwer A, van der Burg B. Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays. Toxicol Sci 2005;83:136-148.
34. Hsieh RW, Rajan SS, Sharma SK, Guo Y, DeSombre ER, Mrksich M, Greene GL. Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity. J Biol Chem 2006;281:17909-17919.
35. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-5930.
36. Enmark K, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjö ld M, Gustafsson JA. Human estrogen receptor b-gene structure, chromosomal localization, and expression pattern. J Clin EndocrinolMetab 1997;82:4258-4265.
37. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997;57:4987-4991.
38. Saunders PTK, Millar MR, Williams K, Macpherson S, Bayne C, O'Sullivan C, Anderson TJ, Groome NP, Miller WR. Expression of oestrogen receptor beta (ERbI) protein in human breast cancer biopsies. Br J Cancer 2002;86:250-256.
39. Middleton LP, Perkins GH, Tucker SL, Sahin AA, Singletary SE. Expression of ERa AND b in lobular carcinoma in situ. Histopathology 2007;50:875-880.
40. Murphy CE, Carder PJ, Lansdown MRJ, Speirs V. Steroid hormone receptor expression in male breast cancer. Eur J Surg Oncol 2006;32:44-47.
41. Saji S, Hirose M, Toi M. Clinical significance of estrogen receptor b in breast cancer. Cancer Chemother Pharmacol 2005;56:s21-s26.
42. Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC. Expression of oestrogen receptor-b in oestrogen receptor-a negative human breast tumours. Br J Cancer 2006;95:616-626.
43. Skliris GP, Leygue E, Watson PH, Murphy LC. Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem and Mol Biol 2008;109:1-10.
44. Behrens D, Gill JH, Fichtner I. Loss of tumourigenicity of stably ERb-transfected MCF-7 breast cancer cells. Mol Cellular Endocrinol 2007;274:19-29.
45. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson JA, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ERb at AP1 sites. Science 1997;277: 1508-1510.
46. Gougelet A, Mueller SO, Korach KS, Renoir JM. Oestrogen receptors pathways to oestrogen responsive elements: the transactivation function-1 acts as the keystone of oestrogen receptor (ER)b-mediated transcriptional repression of ERa. J Steroid Biochem Mol Biol 2007;104:110-112.
47. Day JK, Besch-Williford C, McMann TR, Hufford MG, Lubahn DB, MacDonald RS. Dietary genistein increased DMBA-induced mammary adenocarcinoma in wild-type, but not ERaKO, mice. Nutr Cancer 2001;39:226-232.
48. Routledge EJ, White R, Parker MG, Sumpter JP. Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta. J Biol Chem 2000;275:35986-35993.
49. Chang EC, Charn TH, Park S-H, Helferich WG, Komm B, Katzenellenbogen JA, Katzenellenbogen BS. Estrogen receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding. Mol Endocrinol 2008;22:1032-1043.
50. Brooks JD, Thompson LU. Mammalian lignans and genistein decrease the activities of aromatase and 17[beta]- hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol 2005;94:461-467.
51. Almstrup K, Fernández MF, Petersen JH, Olea N, Skakkebæk NE, Leffers H. Dual effects of phytoestrogens result in U-shaped dose-response curves. Environ Health Perspect 2002;110:743-748.
52. Wang Y, Man Gho W, Chan FL, Chen S, Leung LK. The red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression. Br J Nutr 2007;99:303-310.
53. Whitehead SA, Lacey M. Phytoestrogens inhibit aromatase but not 17{beta}-hydroxysteroid dehydrogenase (HSD) type 1 in human granulosa-luteal cells: evidence for FSH induction of 17{beta}-HSD. Hum Reprod 2003;18:487-494.
54. Brueggemeier RW, Gu X, Mobley JA, Joomprabutra S, Bhat AS, Whetstone JL. Effects of phytoestrogens and synthetic combinatorial libraries on aromatase, estrogen biosynthesis, and metabolism. Ann N Y Acad Sci 2001;948:51-66.
55. Mäkelä S, Poutanen M, Lehtimaki J, Kostian ML, Santti R, Vihko R. Estrogen-specific 17 beta-hydroxysteroid oxidoreductase type 1 (E.C. 1.1.1.62) as a possible target for the action of phytoestrogens. Proc Soc Exp Biol Med 1995;208:51-59.
56. Blomquist CH, Lima PH, Hotchkiss JR. Inhibition of 3ahydroxysteroid dehydrogenase (3a-HSD) activity of human lung microsomes by genistein, daidzein, coumestrol and C 18-, C19- and C21-hydroxysteroids and ketosteroids. Steroids 2005;70:507-514.
57. Kirk CJ, Harris RM, Wood DM,Waring RH, Hughes PJ. Do dietary phytoestrogens influence susceptibility to hormonedependent cancer by disrupting the metabolism of endogenous oestrogens? Biochem Soc Trans 2001;29:209-216.
58. Harris RM, Wood DM, Bottomley L, Blagg S, Owen K, Hughes PJ, Waring RH, Kirk CJ. Phytoestrogens are potent inhibitors of estrogen sulfation: implications for breast cancer risk and treatment. J Clin Endocrinol Metab 2004;89:1779-1787.
59. Loaiza-Perez AI, Trapani V, Hose C, Singh SS, Trepel JB, Stevens MFG, Bradshaw TD, Sausville EA. Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole. Mol Pharmacol 2002;61:13-19.
60. Safe S, Wormke M, Samudio I. Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells. J Mammary Gland Biol Neoplasia 2000;5:295.
61. Chua MS, Kashiyama E, Bradshaw TD, Stinson SF, Brantley E, Sausville EA, Stevens MFG. Role of CYP1A1 in modulation of antitumor properties of the novel agent 2- (4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res 2000;60:5196-5203.
62. Ashida H. Suppressive effects of flavonoids on dioxin toxicity. BioFactors 2000;12:201.
63. Kajta M, Domin H, Grynkiewicz G, Lason W. Genistein inhibits glutamate-induced apoptotic processes in primary neuronal cell cultures: an involvement of aryl hydrocarbon receptor and estrogen receptor/glycogen synthase kinase-3b intracellular signaling pathway. Neuroscience 2007;145:592-604.
64. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-650.
65. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986;78:1287-1295.
66. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARa, b/d and g. J Clin Investig 2004;114:1564-1576.
67. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001;409:307-312.
68. Chacko BK, Chandler RT, D'Alessandro TL, Mundhekar A, Khoo NKH, Botting N, Barnes S, Patel RP. Anti-inflammatory effects of isoflavones are dependent on flow and human endothelial cell PPARg. J Nutr 2007;137:351-356.
69. Ricketts ML, Moore DD, Banz WJ, Mezei O, Shay NF. Molecular mechanisms of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A review. J Nutr Biochem 2005;16:321-330.
70. Kwon DY, Jang JS, Lee JE, Kim YS, Shin DH, Park S. The isoflavonoid aglycone-rich fractions of Chungkookjang, fermented unsalted soybeans, enhance insulin signaling and peroxisome proliferator-activated receptor-g activity in vitro. BioFactors 2006;26:245-258.
71. Dang ZC, Audinot V, Boutin JA, Lowik CWGM. Peroxisome proliferator-activated receptor g (PPARg) as a molecular target for the soy phytoestrogen genistein. J Biol Chem 2003;278:962-967.
72. Kim S, Shin HJ, Kim SY, Kim JH, Lee YS, Kim DH, Lee MO. Genistein enhances expression of genes involved in fatty acid catabolism through activation of PPARa. Mol Cellular Endocrinol 2004;220:51-58.
73. Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr 2003;133:1238-1243.
74. Shen P, Liu MH, Ng TY, Chan YH, Yong EL. Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARa, PPARg, and adipocyte differentiation in vitro. J Nutr 2006;136:899-905.
75. Dang Z, Lowik CWGM. The balance between concurrent activation of ERs and PPARs determines daidzein-induced osteogenesis and adipogenesis. J Bone Miner Res 2004;19:853-861.
76. Rayalam S, Della-Fera MA, Yang JY, Hea JP, Ambati S, Baile CA. Resveratrol potentiates genistein's antiadipogenic and proapoptotic effects in 3T3-L1 adipocytes. J Nutr 2007;137:2668-2673.
77. Szkudelska K, Nogowski L, Szkudelski T. Genistein, a plantderived isoflavone, counteracts the antilipolytic action of insulin in isolated rat adipocytes. J Steroid Biochem Mol Biol 2008;109:108-114.
78. Shimba S, Wada T, Tezuka M. Arylhydrocarbon receptor (AhR) is involved in negative regulation of adipose differentiation in 3T3-L1 cells: AhR inhibits adipose differentiation independently of dioxin. J Cell Sci 2001;114:2809-2817.
79. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005;102:10610-10615.
80. Klö ting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schön MR, Stumvoll M, Blüher M. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006;339:430-436.
81. Rachon D, Mysliwska J, Suchecka-Rachon K, Wieckiewicz J, Mysliwski A. Effects of oestrogen deprivation on interleukin- 6 production by peripheral blood mononuclear cells of postmenopausal women. J Endocrinol 2002;172:387-395.
82. Masiukiewicz US, Mitnick M, Grey AB, Insogna KL. Estrogen modulates parathyroid hormone-induced interleukin- 6 production in vivo and in vitro. Endocrinology 2000;141:2526-2531.
83. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003;32:1-7.
84. NuttallME, Gimble JM. Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis? Bone 2000;27:177-184.
85. Heim M, Frank O, Kampmann G, Sochocky N, Pennimpede T, Fuchs P, Hunziker W, Weber P, Martin I, Bendik I. The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of human primary bone marrow stromal cells. Endocrinology 2004;145:848-859.
86. Li XH, Zhang JC, Sui SF, Yang MS. Effect of daidzin, genistin, and glycitin on osteogenic and adipogenic differentiation of bone marrow stromal cells and adipocytic transdifferentiation of osteoblasts. Acta Pharmacol Sin 2005;26:1081-1086.
87. Schmitt E, Dekant W, Stopper H. Assaying the estrogenicity of phytoestrogens in cells of different estrogen sensitive tissues. Toxicol in Vitro 2001;15:433-439.
88. Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dosedependent manner. Cancer Res 2001;61:5045-5050.
89. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptorpositive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 1998;58:3833-3838.
90. Ju YH, Allred CD, Allred KF, Karko KL, Doerge DR, Helferich WG. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogendependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr 2001;131:2957-2962.
91. Maggiolini M, Bonofiglio D, Marsico S, Panno ML, Cenni B, Picard D, Andò S. Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol 2001;60:595-602.
92. Seo HS, DeNardo DG, Jacquot Y, Laios I, Vidal DS, Zambrana CR, Leclercq G, Brown PH. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res Treat 2006;99:121-134.
93. van Meeuwen JA, ter Burg W, Piersma AH, van der Berg M, Sanderson JT. Mixture effects of estrogenic compounds on proliferation and pS2 expression of MCF-7 human breast cancer cells. Food Chem Toxicol 2007;45:2319-2330.
94. Wang TTY, Sathyamoorthy N, Phang JM. Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis 1996;17:271-275.
95. Wang W, Tanaka Y, Han Z, Higuchi CM. Proliferative response of mammary glandular tissue to formononetin. Nutr Cancer 1995;23:131-140.
96. Guo JM, Xiao BX, Liu DH, Grant M, Zhang S, Lai YF, Guo YB, Liu Q. Biphasic effect of daidzein on cell growth of human colon cancer cells. Food Chem Toxicol 2004;42:1641-1646.
97. Yin CP, Fan LC, He JW, Liu MN, Wang YQ, Zhang ZY. Effect of red clover total isoflavones on cell proliferation and apoptosis of human breast cancer cell line MCF-7. Chin Traditional Herbal Drugs 2007;38:232-234.
98. Bochar DA, Wang L, Beniya H, Kinev A, Xue Y, Lane WS, Wang W, Kashanchi F, Shiekhattar R. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 2000;102:257-265.
99. Chiba N, Parvin JD. Redistribution of BRCA1 among four different protein complexes following replication blockage. J Biol Chem 2001;276:38549-38554.
100. Le Page F, Randrianarison V, Marot D, Cabannes J, Perricaudet M, Feunteun J, Sarasin A. BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res 2000;60:5548-5552.
101. Patel KJ, Yu VPCC, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BAJ, Venkitaraman AR. Involvement of Brca2 in DNA repair. Mol Cell 1998;1:347-357.
102. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-182.
103. Venkitaraman AR. Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci 2001;114: 3591-3598.
104. Bonorden MJL, Greany KA, Wangen KE, Feirtag J, Kurzer MS, Phipps WR, Adlercreutz H. Consumption of Lactobacillus acidophilus and Bifidobacterium longum do not alter urinary equol excretion and plasma reproductive hormones in premenopausal women. Eur J Clin Nutr 2004;58:1635.
105. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000;14:927-939.
106. Caetano B, Le Corre L, Chalabi N, Delort L, Bignon YJ, Bernard-Gallon DJ. Soya phytonutrients act on a panel of genes implicated with BRCA1 and BRCA2 oncosuppressors in human breast cell lines. Br J Nutr 2006;95:406-413.
107. Fan S, Meng Q, Auborn K, Carter T, Rosen EM. BRCA1 and BRCA2 as molecular targets for phytochemicals indole- 3-carbinol and genistein in breast and prostate cancer cells. Br J Cancer 2006;94:407-426.
108. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005;65:6934-6942.
109. Li Y, Bhuiyan M, Sarkar FH. Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Int J Oncol 1999;15:525-533.
110. Li Y, Upadhyay S, Bhuiyan M, Sarkar FH. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 1999;18:3166-3172. (Pubitemid 29261238)
111. Mai Z, Blackburn GL, Zhou JR. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. Mol Carcinog 2007;46:534-542.
112. Mak P, Leung YK, Tang WY, Harwood C, Ho SM. Apigenin suppresses cancer cell growth through ERbeta. Neoplasia 2006;8:896-904.
113. Peterson G, Barnes S. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun 1991;179:661-667.
114. Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, Hillman GG. Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 2006;6:107.
115. Shao ZM, Alpaugh ML, Fontana JA, Barsky SH. Genistein inhibits proliferation similarly in estrogen receptor-positive and negative human breast carcinoma cell lines characterized by P21WAF1/CIP1 induction, G2/M arrest, and apoptosis. J Cell Biochem 1998;69:44-54.
116. Shao ZM, Wu J, Shen ZZ, Barsky SH. Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res 1998;58:4851-4857.
117. Upadhyay S, Neburi M, Chinni SR, Alhasan S, Miller F, Sarkar FH. Differential sensitivity of normal and malignant breast epithelial cells to genistein is partly mediated by p21(WAF1). Clin Cancer Res 2001;7:1782-1789.
118. Yang S, Zhou Q, Yang X. Caspase-3 status is a determinant of the differential responses to genistein between MDA-MB- 231 and MCF-7 breast cancer cells. Biochim Biophys Acta 2007;1773:903-911.
119. Davis NJ, Singh B, Bhuiyan M, Sarkar FH. Genisteininduced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer 1998;32:123-131.
120. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 1999;129:1628-1635.
121. Yu Z, Li W, Liu F. Inhibition of proliferation and induction of apoptosis by genistein in colon cancer HT-29 cells. Cancer Lett 2004;215:159-166.
122. Su S-J, Yeh T-M, Lei H-Y, Chow N-H. The potential of soybean foods as a chemoprevention approach for human urinary tract cancer. Clin Cancer Res 2000;6:230-236.
123. Bergamaschi G, Rosti V, Danova M, Ponchio L, Lucotti C, Cazzola M. Inhibitors of tyrosine phosphorylation induce apoptosis in human leukemic cell lines. Leukemia 1993;7:2012-2018.
124. Jin CY, Park C, Cheong J, Choi BT, Lee TH, Lee JD, Lee WH, Kim GY, Ryu CH, Choi YH. Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. Cancer Lett 2007;257:56-64.
125. Yanagihara K, Ito A, Toge T, Numoto M. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res 1993;53:5815-5821.
126. Lian F, Bhuiyan M, Li YW, Wall N, Kraut M, Sarkar FH. Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer 1998;31:184-191. (Pubitemid 28481852)
127. Lian F, Li Y, Bhuiyan M, Sarkar FH. p53-independent apoptosis induced by genistein in lung cancer cells. Nutr Cancer 1999;33:125-131. (Pubitemid 29269998)
128. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 2006;5:483-493.
129. Chang KL, Kung ML, Chow NH, Su SJ. Genistein arrests hepatoma cells at G2/M phase: involvement of ATM activation and upregulation of p21waf1/cip1 and Wee1. Biochem Pharmacol 2004;67:717-726.
130. Chodon D, Ramamurty N, Sakthisekaran D. Preliminary studies on induction of apoptosis by genistein on HepG2 cell line. Toxicol In Vitro 2007;21:887-891.
131. Gu Y, Zhu CF, Iwamoto H, Chen JS. Genistein inhibits invasive potential of human hepatocellular carcinoma by altering cell cycle, apoptosis, and angiogenesis. World J Gastroenterol 2005;11:6512-6517.
132. Sasamura H, Takahashi A, Yuan J, Kitamura H, Masumori N, Miyao N, Itoh N, Tsukamoto T. Antiproliferative and antiangiogenic activities of genistein in human renal cell carcinoma. Urology 2004;64:389-393.
133. Guo JM, Kang GZ, Xiao BX, Liu DH, Zhang S. Effect of daidzein on cell growth, cell cycle, and telomerase activity of human cervical cancer in vitro. Int J Gynecol Cancer 2004;14:882-888.
134. Wu CP, Calcagno AM, Hladky SB, Ambudkar SV, Barrand MA. Modulatory effects of plant phenols on human multidrug- resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J 2005;272:4725-4740.
135. Atkin GK, Chopada A. Tumour angiogenesis: the relevance to surgeons. Ann Royal Coll Surg England 2006;88:525-529.
136. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000;52:237-268.
137. Bikfalvi A. Platelet factor 4: an inhibitor of angiogenesis. Semin Thromb Hemostasis 2004;30:379-385.
138. Su SJ, Yeh TM, Chuang WJ, Ho CL, Chang KL, Cheng KL, Liu HS, Cheng HL, Hsu PY, Chow NH. The novel targets for anti-angiogenesis of genistein on human cancer cells. Biochem Pharmacol 2005;69:307-318.
139. Guo Y, Wang S, Hoot DR, Clinton SK. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J Nutr Biochem 2007;18:408-417.
140. Piao M, Mori D, Satoh T, Sugita Y, Tokunaga O. Inhibition of endothelial cell proliferation, in vitro angiogenesis, and the down-regulation of cell adhesion-related genes by genistein. Combined with a cDNA microarray analysis. Endothelium 2006;13:249-266.
141. Büchler P, Reber HA, Büchler MW, Friess H, Lavey RS, Hines OJ. Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxiainducible factor-1 and the down-regulation of VEGF gene expression. Cancer 2004;100:201-210.
142. Huang X, Chen S, Xu L, Liu Y, Deb DK, Platanias LC, Bergan RC. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 2005;65:3470-3478.
143. Feghali CA, Wright TM. Cytokines in acute and chronic inflammation. Frontiers Biosci 1997;2:d12-d26.
144. Koj A. Initiation of acute phase response and synthesis of cytokines. Biochim Biophys Acta 1996;1317:84-94.
145. Vande Berghe W, De Bosscher K, Boone E, Plaisance S, Haegeman G. The nuclear factor-kB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J Biol Chem 1999;274:32091-32098.
146. Vanden Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W, Haegeman G. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kB p65 transactivation mediated by tumor necrosis factor. J Biol Chem 1998;273:3285-3290.
147. Verhasselt V, Vanden Berghe W, Vanderheyde N, Willems F, Haegeman G, Goldman M. N-acetyl-L-cysteine inhibits primary human T cell responses at the dendritic cell level: association with NF-kB inhibition. J Immunol 1999;162: 2569-2574.
148. Raschke M, Rowland IR, Magee PJ, Pool-Zobel BL. Genistein protects prostate cells against hydrogen peroxideinduced DNA damage and induces expression of genes involved in the defence against oxidative stress. Carcinogenesis 2006;27:2322-2330.
149. Li Y, Ellis KL, Ali S, El-Rayes BF, Nedeljkovic-Kurepa A, Kucuk O, Philip PA, Sarkar FH. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas 2004;28:e90-e95.
150. Chen X, Anderson JJ. Isoflavones inhibit proliferation of ovarian cancer cells in vitro via an estrogen receptordependent pathway. Nutr Cancer 2001;41:165-171.
151. Vanden Berghe W, Dijsselbloem N, Vermeulen L, Ndlovu MN, Boone E, Haegeman G. Attenuation of mitogen- and stress-activated protein kinase-1-driven nuclear factor-kappaB gene expression by soy isoflavones does not require estrogenic activity. Cancer Res 2006;66:4852-4862.
152. Thompson D, Whicher JT, Evans SW. Interleukin 6 signal transduction in a human hepatoma cell line (Hep G2). Immunopharmacol Immunotoxicol 1993;15:371-386.
153. Parikh AA, Salzman AL, Kane CD, Fischer JE, Hasselgren PO. IL-6 production in human intestinal epithelial cells following stimulation with IL-1
154. Pool-Zobel BL, Adlercreutz H, Glei M, Liegibel UM, Sittlingon J, Rowland I, Wähälä K, Rechkemmer G. Isoflavonoids and lignans have different potentials to modulate oxidative genetic damage in human colon cells. Carcinogenesis 2000;21:1247-1252.
155. Constantinou AI, Krygier AE, Mehta RR. Genistein induces maturation of cultured human breast cancer cells and prevents tumor growth in nude mice. Am J Clin Nutr 1998;68:1426S-1430S.
156. Vantyghem SA, Wilson SM, Postenka CO, Al-Katib W, Tuck AB, Chambers AF. Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model. Cancer Res 2005;65:3396-3403.
157. Mohammad RM, Banerjee S, Li Y, Aboukameel A, Kucuk O, Sarkar FH. Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer 2006;106:1260-1268.
158. Rice L, Samedi VG, Medrano TA, Sweeney CA, Baker HV, Stenstrom A, Furman J, Shiverick KT. Mechanisms of the growth inhibitory effects of the isoflavonoid biochanin A on LNCaP cells and xenografts. Prostate 2002;52:201-212.
159. Ju YH, Fultz J, Allred KF, Doerge DR, Helferich WG. Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogendependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice. Carcinogenesis 2006;27:856-863.
160. Ju YH, Doerge DR, Helferich WG. A dietary supplement for female sexual dysfunction, Avlimil, stimulates the growth of estrogen-dependent breast tumors (MCF-7) implanted in ovariectomized athymic nude mice. Food Chem Toxicol 2008;46:310-320.
161. Banerjee S, Zhang Y, Wang Z, Che M, Chiao PJ, Abbruzzese JL, Sarkar FH. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer 2007;120:906-917. (Pubitemid 46175414)
162. Chung SY, Sung MK, Kim NH, Jang JO, Go EJ, Lee HJ. Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch Pharm Res 2005;28:823-828.
163. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG. Overexpression of a transporter gene in a multidrugresistant human lung cancer cell line. Science 1992;258:1650-1654.
164. Raffoul JJ, Banerjee S, Che M, Knoll ZE, Doerge DR, Abrams J, Kucuk O, Sarkar FH, Hillman GG. Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model. Int J Cancer 2007;120:2491-2498. (Pubitemid 46642139)
165. Raffoul JJ, Banerjee S, Singh-Gupta V, Knoll ZE, Fite A, Zhang H, Abrams J, Sarkar FH, Hillman GG. Downregulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo. Cancer Res 2007;67:2141-2149.
166. Shen J, Tai YP, Zhou J, Stephen Wong CH, Cheang PT, Fred Wong WS, Xie Z, Khan M, Han JH, Chen CS. Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling. Exp Hematol 2007;35:75-83.
167. Versantvoort CH, Schuurhuis GJ, Pinedo HM, Eekman CA, Kuiper CM, Lankelma J, Broxterman HJ. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer 1993;68:939-946.
168. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 2003;304:1258-1267.
169. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;445:152-162.
170. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983;221:1285-1288.
171. Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 2004;65:1208-1216. (Pubitemid 38543491)